MAPT and Alzheimer disease: Indeed, one such kinase, GSK-3β, has already been implicated in both tau phosphorylation during LTD (Bradley et al., 2012; Kimura et al., 2013) and in the pathological phosphorylation events additionally required for the development of AD phenotypes (Deng et al., 2014; Jo et al., 2011; Shipton et al., 2011; Yi et al., 2018), including phosphorylation of tau residues recognized by the phosphorylation state-specific antibody AT8 (Liu et al., 2002; Wang et al., 1998).